Speakers

Expand/Collapse

Susan Abushakra
Chief Medical Officer
Alzheon

One-Day Digital Content

Wednesday | July 15, 2020

2:20 pm | Live Q&A – Fire Away & Ask Those Questions!

1:50 pm | ALZ-801 Phase 3-Ready Program: A Targeted Therapy for Alzheimer’s Disease

Isaac Galatzer-Levy
Chief Scientific Officer
AiCure

Dr Isaac Galatzer-Levy leads AiCure’s research and development (R&D) team on the development of AI based models to characterize illness, predict treatment course, and select treatments based on digital phynotyping, or measurement of clinical functioning based on digital behavior. Dr Galatzer-Levy’s background is in machine learning/AI, neuroscience, and clinical psychology. Dr Galatzer-Levy has lead large teams of researchers, received NIH, DOD, and foundation funding, published over 75+ peer-reviewed publications, and has contributed significantly to the emerging field of digital mental health. In both academia and industry, he has lead efforts in biomarker and digital marker development for prediction and phenotyping across diverse neuropsychiatric diseases.

One-Day Digital Content

Wednesday | July 15, 2020

2:20 pm | Live Q&A – Fire Away & Ask Those Questions!

1:40 pm | Mobile Deployment of Validated Visual And Audio Markers Of Neurodegenerative Disease   

1:00 pm | Panel Discussion: Advancing Digital Biomarkers for Neurodegenerative Diseases

Tatiana Plavina
VP of Clinical Strategy
Quanterix

Dr. Tatiana Plavina, VP of Clinical Strategy at Quanterix, is a seasoned biomarker researcher, and is responsible for clinical biomarker strategy in neurodegenerative diseases. Prior to Quanterix, Dr. Plavina was with Biogen for 18 years, holding several senior roles in R&D and Medical organizations including biomarker lead for several development programs and in Medical organization, and oversight of the biobank for the large real-world MS PATHS study. Her accomplishments include role in development and implementation in clincial care of the STRATIFY JCV™ assay for PML risk stratification, and evidence generation for serum neurofilament light chain (Nf-L) as a prognostic and treatment monitoring biomarker in multiple sclerosis. Tatiana holds M.S. degree in Physics and Chemical Biology from the Moscow Institute of Physics and Technology, and Ph.D. degree in Chemistry and Chemical Biology from the Northeastern University. She has numerous publications in peer-reviewed journals, holds patents, and is a regular presenter at the International Scientific Conferences.

One-Day Digital Content

Wednesday | July 15, 2020

9:30 am | Novel Simoa p-tau181 Blood Immunoassay to Support Research, Therapeutics Development & Clinical Care of Alzheimer’s Disease

10:00 am | Live Q&A

Giulio Maria Pasinetti
Saunders Family Chair & Professor of Neurology, Psychiatry & Neuroscience, Geriatrics & Adult Development
Icahn School of Medicine, Mount Sinai

Dr. Giulio Maria Pasinetti is the The Saunders Family Chair and Professor of Neurology, Neuroscience, and Geriatrics and Adult Development at the Ichan School of Medicine at Mount Sinai (ISMMS) in NY. He also serves as the Director of  Basic and Biomedical Research in the Center for Geriatic Research and Training at the Bronx Veterans Affairs Medical Center. He is also the Director of the Center for Molecular Integrative Neuroresilience at the ISMMS. The Center’s goal is to understand the mechanisms of action through which novel therapeutics act against stressful events and to clarify the role of innate immunity in the gut/microbiome-brain axis at the genomic level in the promotion of cognitive and psychological resilience across the lifespan.

On-Demant Content

10:00 am | Biomarkers of Chronic Stress Induced Psychological Impairment in Dementia through Gut-Brain-Axis Immune Mechanisms

One-Day Digital Content

Wednesday | July 15, 2020

4:05 pm | Live Q&A – Fire Away & Ask Those Questions!

Christopher Whelan
Senior Scientist
Biogen

Dr. Whelan is a Senior Scientist in the Translational Biology research group at Biogen. He received his Ph.D. from the Royal College of Surgeons in Ireland in 2014, and completed a post-doctoral fellowship with the ENIGMA consortium, based in the University of Southern California, from 2014 to 2016. Chris’s graduate and post-doctoral research focused on the combination of genome-wide association data with magnetic resonance imaging scans, leading to the world’s largest studies of genetic susceptibility towards and structural alterations across the epilepsies (Whelan/ILAE Consortium, Lancet Neurology, 2014, Whelan et al., Brain, 2018), as well as genetic determinants of brain morphology (Hibar et al., Nature, 2015),. In 2016, Chris joined Pfizer R&D, where he served as the scientific strategy lead for human genetics, functional genomics, and biomarker discovery projects supporting the company’s Neuroscience Research Unit. He moved to Biogen in 2018, where his research has focused on applying quantitative genetics and biomarker discovery to help accelerate drug discovery programs and integrate precision medicine strategies for neurodegenerative illnesses.

One-Day Digital Content

Wednesday | July 15, 2020

4:05 pm | Live Q&A – Fire Away & Ask Those Questions!

3:25 pm | Combining Genomics & Multiplex Proteomic Profiling for Alzheimer’s Disease Drug Discovery & Development

Danielle Graham
Senior Director, Discovery & Clinical Biomarkers
Biogen

Dr. Danielle Graham received her Ph.D. in Neuroscience from Baylor University in 2002.  She completed her postdoctoral research at the University of Texas Southwestern Medical Center in Dallas, TX working with Dr. David Self and Dr. Eric Nestler.  Dr. Graham moved to Boston MA in 2007 to join the AD group at Merck Research Labs (MRL).  In 2009, Dr. Graham moved to EMD Serono Research Institute, where as a group leader she was responsible for leading a team of scientists in the identification and characterization of novel therapeutics and translational endpoints for CNS Disease.  In 2014, Dr. Graham moved to Biogen in Cambridge MA and is currently Sr Director, Discovery and Clinical Biomarkers leading a brilliant team of scientists who are focused on the development of novel fluid biomarkers in Neurodegenerative Disease including AD.  Two key objectives of her team are to develop novel biomarkers that help de-risk therapeutic development in early clinical studies as well as advance disease relevant biomarkers that provide an early indicator of clinical efficacy.

One-Day Digital Content

Wednesday | July 15, 2020

12:00 pm | Live Q&A – Fire Away & Ask Those Questions!

11:20 am | Employing Biomarkers to De-risk Therapeutic Development in AD

Lindsay Burns
SVP of Neuroscience
Cassava Sciences, Inc

Lindsay H. Burns, PhD, is lead scientist on Cassava Sciences’ program in Alzheimer’s disease.  She and Dr. Hoau-Yan Wang co-discovered and developed PTI-125, a novel drug candidate for AD and other neurodegenerations. Dr. Burns has led the program through basic research, target identification & validation, medicinal chemistry, lead discovery & profiling, compound pharmacology, mechanism-of-action studies, IND-enabling studies and, more recently, clinical studies in patients with Alzheimer’s disease. Trained in neuropsychology at the University of Cambridge and Harvard College, Dr. Burns has a broad background in neuroscience and neurodegenerative disease that spans functional in vitro assays, preclinical models of disease and cognitive/behavioral testing

One-Day Digital Content

Wednesday | July 15, 2020

10:00 am | Live Q&A

9:10 am | SavaDx, an Investigational Blood-Based AD Diagnostic/Biomarker

Richard Wyse
Global Director of Research and Development
Cure Parkinson’s Trust UK

Dr Richard Wyse is Director of Research and Development at The Cure Parkinson’s Trust (CPT). His role is to monitor scientific and medical developments into the causes and treatment of Parkinson's disease to design and foster promising new lines of therapeutic research and to promote beneficial worldwide scientific and clinical collaborations across the Parkinson's community. CPT’s International PD Linked Clinical Trials (LCT) programme, involving a committee of 21 world expert in PDs, and currently, 24 separate ongoing clinical trials, is his brainchild. Richard also sits on CPT’s Research Committee, as well as the Research Committee of the Michael J Fox Foundation, and the Australian Parkinson’s Mission.

One-Day Digital Content

Wednesday | July 15, 2020

5:50 pm | Live Q&A – Fire Away & Ask Those Questions!

5:30 pm | Translating Key Developments in Biomarker Studies in Parkinson’s to Help Advance Disease Modifying Therapeutics for AD

Christopher Winrow
Senior Director, Clinical Development - Neuroscience Program Lead
Cyclerion

Christopher Winrow is the Senior Director, Clinical Development and Neuroscience Program Lead at Cyclerion Therapeutics in Cambridge, MA. Prior to Cyclerion, Dr. Winrow held roles of increasing responsibility at Merck & Co., Inc. and Ironwood Pharmaceuticals. He completed his Ph.D. at the University of Alberta and post-doc at the Salk Institute. Dr. Winrow has an extensive background in CNS diseases with areas of focus including Alzheimer’s disease, Parkinson’s disease, dementia, sleep disorders, autism, and orphan diseases. He authored more than 75 publications, is co-inventor on multiple patents, co-authored 10 eIND/INDs and has over 15 years of neuroscience drug discovery and development experience. Dr. Winrow delivered five CNS compounds from screening through successful clinical POC. He led the Belsomra® discovery team from screening to regulatory approval in less than 10 years, resulting in approvals by U.S. and international regulatory agencies. He currently leads multidisciplinary drug discovery and development teams for serious and orphan diseases at Cyclerion Therapeutics

One-Day Digital Content

Wednesday | July 15, 2020

12:00 pm | Live Q&A – Fire Away & Ask Those Questions!

11:00 am | Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies

Christopher (CJ) Barnum
Director of Neuroscience
INmune Bio

Dr. Barnum is the Director of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases whose work has focused on identifying biomarkers that can be used to translate inflammatory therapies into clinical treatments for neurologic diseases.

One-Day Digital Content

Wednesday | July 15, 2020

4:05 pm | Live Q&A – Fire Away & Ask Those Questions!

3:05 pm | One Size Does Not Fit All: Inflammatory Biomarkers Across the Disease & Drug Development Spectrum

Dimitrios Kapogiannis
Clinical Investigator, Laboratory of Clinical Investigation, National Institute on Aging, NIH , Adjunct Associate Professor, Dept. of Neurology
National Institute of Health

Dimitrios Kapogiannis earned his Medical Degree from the National University of Athens, Greece, and completed his Neurology residency training at the combined program of Massachusetts General and Brigham and Women’s Hospitals, followed by a clinical fellowship at the Cognitive Neuroscience Section at NINDS/NIH. He is ABPN-certified in Neurology and an Adjunct Associate Professor at the Department of Neurology at Johns Hopkins University. He conducts translational and clinical studies on cognitive aging and various neurodegenerative diseases, with a primary focus on biomarkers of Alzheimer’s disease by deriving exosomes enriched for neuronal origin from plasma and using them as a source of biomarkers for various diseases.

One-Day Digital Content

Wednesday | July 15, 2020

10:00 am | Live Q&A

9:40 am | Exosomes: Drivers in AD Pathogenesis & a Valid Source of Biomarkers

Scott Shandler
Founder & CEO
Longevity Biotech

Dr. Shandler brings over a decade of various commercial and scientific operating experiences to Longevity. Prior to founding Longevity, Dr. Shandler was a venture capitalist at BioAdvance, an early stage fund based in Philadelphia, where he was responsible for therapeutics, diagnostic and biomarker opportunities. Prior to BioAdvance, Dr. Shandler was a portfolio analyst for Merck Research Labs (MRK) where he developed a forecasting model and framework to guide preclinical project prioritization efforts across several therapeutic areas. Prior to Merck, Dr. Shandler was a product manager for PolyMedix (PYMX.OB), an early stage biotech company developing antimicrobial and cardiovascular therapeutics. While at PolyMedix, Dr. Shandler assisted with their successful Series A fundraising activities. Dr. Shandler also served as a consultant and subject matter expert in Accenture’s (ACN) Pharmaceutical and Medical Products group, advising leading pharmaceutical and biotechnology companies on technology and strategy matters. Earlier in his career, he worked for Inventa, a Silicon Valley startup helping craft business solutions for Fortune 500 and startup companies alike. Dr. Shandler received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania, an MBA from The Wharton School in the Healthcare department, a Certificate of Bioinformatics from Stanford University along with a B.A. in Computer Science from Brandeis University. Dr. Shandler has published in various leading peer reviewed journals, is an inventor on multiple patents and has served as Principal Investigator on various federal and private grants.

One-Day Digital Content

Wednesday | July 15, 2020

5:50 pm | Live Q&A – Fire Away & Ask Those Questions!

4:50 pm | Immune Dysfunction in Parkinson’s Disease: Insights into Neuroinflammation

Rhoda Au
Professor of Anatomy, Neurobiology
Framingham Heart Study, Boston University Schools of Medicine

Dr. Au’s research interests are focused on aging and dementia, and include relating cardiovascular risk factors, brain MRI measures, and neuropathology to cognitive performance. She is also interested in merging research and technology as the path toward innovative science.

One-Day Digital Content

Wednesday | July 15, 2020

2:20 pm | Live Q&A – Fire Away & Ask Those Questions!

1:00 pm | Panel Discussion: Advancing Digital Biomarkers for Neurodegenerative Diseases

Daniel Alkon
Scientific Director
Neuro Diagnostics LLC

Dr. Alkon has served as President and Chief Scientific Officer of Neurotrope, Inc. since September 2016. He also serves as Scientific Director, Neurodiagnostics.  A leader in the field, Dr. Alkon came to Neurotrope after 30 years directing programs on the molecular and structural basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller Neuroscience Institute.  He and his teams developed neurorestorative therapeutics for degenerative disorders of the central nervous system (such as Alzheimer’s disease – AD) as well as non-invasive Biomarkers for AD. He also served as the Toyota Chair of Neurodegenerative Diseases, Professor of Neurology at West Virginia University, and Research Professor, Johns Hopkins University. An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins. Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York

One-Day Digital Content

Wednesday | July 15, 2020

12:00 pm | Live Q&A – Fire Away & Ask Those Questions!

11:40 am | Therapeutic & Diagnostic Biomarkers that Target Synaptic Loss in AD

Jonathan Levenson
Vice President of Translational Biology
Tiaki Therapeutics

Jonathan Levenson is the VP of Translational Biology at Tiaki Therapeutics. He previously served as the VP of preclinical research and development at Proclara, where he oversaw two preclinical programs characterizing novel biological therapeutics targeting misfolded proteins in neurodegenerative, orphan and metabolic disease. Prior to joining Proclara, he worked at Galenea, a drug development company focusing on the cognitive symptoms of psychiatric disorders, where he held positions of increasing responsibility, culminating in the role of senior scientist. Before that, Dr. Levenson was an assistant professor and the director of the rodent behavioral core at the University of Wisconsin-Madison. He was previously a consultant at Saegis Pharmaceuticals and an assistant professor at Baylor College of Medicine. Dr. Levenson earned his Bachelor of Science, cum laude, from Vanderbilt University, his doctorate in Biology from the University of Houston, and was a postdoctoral fellow at the Baylor College of Medicine.  He has authored or co-authored over 60 research publications focused on neuropharmacology and the treatment of neurological diseases.

One-Day Digital Content

Wednesday | July 15, 2020

4:05 pm | Live Q&A – Fire Away & Ask Those Questions!

3:45 pm | Finding the Right Patients: Can Genetics Inform Selection of Fluid Biomarkers that Identify Subjects with a Specific Disease Biology?

Mark Frasier
Senior Vice President
Research Programs Michael J Fox Foundation

One-Day Digital Content

Wednesday | July 15, 2020

5:50 pm | Live Q&A – Fire Away & Ask Those Questions!

1:00 pm | Panel Discussion: Advancing Digital Biomarkers for Neurodegenerative Diseases

5:10 pm | Accelerating Parkinson’s Disease Outcome Measures: Progress & Challenges

Lindsey Smith PhD
Field Application Scientist
Aiforia

One-Day Digital Content

Wednesday | July 15, 2020

2:20 pm | Live Q&A – Fire Away & Ask Those Questions!

2:10 pm | Accelerating Alzheimer’s Disease Research with AI